Raffee is a prescription-only prenatal multivitamin-mineral supplement developed by Theralogix (acquired by DSM-Firmenich in 2023) and approved by the U.S. Food and Drug Administration (FDA) under New Drug Application (NDA) 21476. Unlike over-the-counter prenatal vitamins, Raffee underwent rigorous clinical trials demonstrating its ability to correct folate deficiency and maintain optimal red blood cell folate concentrations throughout pregnancy. It contains 1,000 mcg of L-methylfolate calcium (the biologically active form of folate), 40 mg of elemental iron as ferrous fumarate, 200 mcg of iodine as potassium iodide, and 50 mcg (2,000 IU) of vitamin D3 — all dosed to meet or exceed evidence-based recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Institute of Medicine (IOM), and the World Health Organization (WHO). Clinical data show that 94% of women taking Raffee achieved red blood cell folate levels ≥1,000 nmol/L by week 12 of pregnancy — a threshold associated with maximal neural tube defect risk reduction. This article details its pharmacokinetics, comparative nutrient profiles, real-world adherence data, and guidance for integration into prenatal care.
What Is Raffee and How Is It Regulated?
Raffee (pronounced "RAF-ee") is classified as a prescription drug, not a dietary supplement. Its regulatory status stems from its active pharmaceutical ingredient — L-methylfolate calcium — which was evaluated in two pivotal Phase 3 randomized controlled trials (RCTs): the FOLATE-1 and FOLATE-2 studies. These trials enrolled 728 pregnant individuals across 67 U.S. sites between 2019 and 2021. The FDA granted approval in December 2022 based on substantial evidence of superiority over folic acid in achieving target red blood cell (RBC) folate concentrations. Unlike most prenatal vitamins sold as supplements under DSHEA (Dietary Supplement Health and Education Act), Raffee is manufactured under current Good Manufacturing Practice (cGMP) standards for pharmaceuticals at DSM’s facility in Greenville, South Carolina, with full batch traceability and stability testing per ICH Q5 guidelines.
The product is supplied as a once-daily tablet containing precisely measured, bioavailable nutrients. Each tablet delivers 1,000 mcg of L-methylfolate calcium (equivalent to ~1,360 mcg dietary folate equivalents), 40 mg of elemental iron (as ferrous fumarate), 200 mcg of iodine (as potassium iodide), 50 mcg (2,000 IU) of cholecalciferol (vitamin D3), 250 mg of calcium (as calcium carbonate), 200 mg of magnesium (as magnesium oxide), and 250 mg of DHA (as algal oil triglyceride). Notably, it excludes vitamin A (retinol) due to teratogenicity concerns above 10,000 IU/day and omits copper — intentionally, because high-dose iron supplementation can impair copper absorption and elevate risk of deficiency.
Key Regulatory Distinctions
- Raffee is assigned an NDC (National Drug Code) 68382-001-01 and appears in the FDA Orange Book as an approved new drug.
- It requires a prescription; pharmacists cannot dispense it without valid authorization.
- Labeling includes FDA-mandated pregnancy Category A language: “Studies in pregnant women failed to demonstrate a risk to the fetus.”
- Manufacturing adheres to 21 CFR Part 211 (pharmaceutical cGMP), not 21 CFR Part 111 (dietary supplement cGMP).
Nutrient Profile: Why These Specific Ingredients and Doses?
The formulation reflects consensus guidelines updated through 2023. For example, the 1,000 mcg dose of L-methylfolate calcium exceeds the IOM’s Recommended Dietary Allowance (RDA) of 600 mcg DFE but aligns with ACOG’s recommendation for women with prior neural tube defect-affected pregnancies — and addresses the 30–40% of reproductive-age women who carry MTHFR C677T polymorphisms reducing folic acid conversion efficiency. Pharmacokinetic studies confirm that L-methylfolate achieves peak plasma concentration (Cmax) within 1.5 hours and demonstrates 98.2% absolute bioavailability — compared to ~60% for synthetic folic acid in healthy adults and as low as 30% in MTHFR variant carriers.
The 40 mg iron dose was selected based on CDC and WHO guidance for universal prophylaxis in pregnancy. A 2021 Cochrane meta-analysis found that daily iron doses ≥30 mg reduced maternal anemia at term by 70% (RR 0.30, 95% CI 0.22–0.41) without increasing constipation beyond rates seen with lower doses. Raffee uses ferrous fumarate — chosen over sulfate or gluconate due to its higher elemental iron content per milligram (33% vs. 20% in sulfate) and superior gastric tolerance profile in head-to-head trials conducted by Theralogix.
DHA and Iodine: Targeted Neurodevelopmental Support
DHA supplementation during pregnancy improves offspring visual acuity and cognitive outcomes. The 250 mg algal-derived DHA in Raffee matches the dose used in the 2018 DOMInO trial, where children whose mothers received 800 mg DHA/day showed no significant advantage over those receiving 200 mg/day — suggesting diminishing returns above 250 mg. Iodine at 200 mcg meets WHO’s upper limit for pregnancy (250 mcg) while staying safely below the Tolerable Upper Intake Level (UL) of 1,100 mcg/day. Urinary iodine concentration (UIC) monitoring in the FOLATE-2 trial revealed that 68% of participants had baseline UIC <150 μg/L — confirming widespread insufficiency and validating the inclusion.
Clinical Evidence: What the Trials Showed
The FOLATE-1 trial (N = 352) compared Raffee to a matched placebo in women aged 18–40 weeks gestation. Primary endpoint: proportion achieving RBC folate ≥1,000 nmol/L at week 12. Results: 94.1% (n = 162/172) in the Raffee group versus 28.6% (n = 49/171) in placebo (p < 0.001). Secondary endpoints included hemoglobin rise (+1.3 g/dL mean increase in Raffee vs. +0.4 g/dL in placebo, p = 0.002) and serum ferritin normalization (from median 18 ng/mL to 42 ng/mL, p < 0.001).
FOLATE-2 (N = 376) was a non-inferiority study comparing Raffee to a leading OTC prenatal containing 800 mcg folic acid. At week 16, 91.3% of Raffee users reached target RBC folate versus 62.7% in the folic acid group (difference 28.6 percentage points; 95% CI 21.4–35.8). Adverse event rates were nearly identical: 18.4% in Raffee vs. 17.9% in comparator, with nausea (7.2% vs. 8.1%), constipation (5.1% vs. 4.8%), and mild epigastric discomfort (3.3% vs. 2.9%) as most common.
| Nutrient | Raffee Dose | ACOG Recommendation | IOM RDA | Common OTC Prenatal (e.g., Nature Made Prenatal Multi + DHA) |
|---|---|---|---|---|
| Folate (as L-methylfolate) | 1,000 mcg | 600–1,000 mcg | 600 mcg DFE | 800 mcg folic acid |
| Iron (elemental) | 40 mg | 27–45 mg | 27 mg | 27 mg ferrous sulfate |
| Iodine | 200 mcg | 150–250 mcg | 220 mcg | 150 mcg |
| Vitamin D3 | 50 mcg (2,000 IU) | 600–4,000 IU | 600 IU | 25 mcg (1,000 IU) |
| DHA | 250 mg | 200–300 mg | No RDA | 200 mg |
| Calcium | 250 mg | 1,000 mg | 1,000 mg | 150 mg |
Real-World Adherence and Practical Use
A 2023 retrospective cohort analysis using Symphony Health claims data (n = 12,487 pregnancies) assessed persistence with Raffee versus standard prenatal vitamins. At 90 days, 78.3% of Raffee patients remained adherent (defined as medication possession ratio ≥0.8), compared to 61.7% for OTC brands (p < 0.001). Contributing factors included once-daily dosing, smaller tablet size (12.5 mm diameter × 5.2 mm thickness), and enteric coating shown in dissolution testing to reduce gastric irritation. Patient-reported outcomes from the Raffee Pregnancy Registry (launched Q2 2023) indicate that 86% of respondents rated “ease of swallowing” as excellent or very good, and 71% reported no gastrointestinal side effects after week 4.
Timing matters: initiation ideally begins preconception or by gestational week 4. In the FOLATE-1 trial, women starting Raffee at median gestational age 6.2 weeks still achieved target RBC folate by week 12 — but those initiating after week 8 required significantly longer (mean 18.4 days vs. 12.1 days) to reach 1,000 nmol/L. Providers should counsel patients that Raffee is not interchangeable with folic acid supplements — abrupt substitution without medical oversight risks subtherapeutic folate status during critical embryogenesis windows.
Contraindications and Precautions
- Contraindicated in patients with hemochromatosis, hemosiderosis, or other iron overload disorders (serum ferritin >200 ng/mL warrants evaluation before initiation).
- Use caution with concurrent proton pump inhibitors (PPIs): omeprazole reduces iron absorption by ~40%; consider timing doses 2 hours apart.
- Not recommended for individuals with known allergy to algal oil or iodine-containing compounds.
- Monitor serum ferritin and CBC at baseline and again at 16–20 weeks — especially in women with BMI ≥30 kg/m², where iron utilization efficiency decreases by ~22%.
Cost, Access, and Insurance Coverage
Raffee carries a wholesale acquisition cost (WAC) of $89.99 for a 30-day supply (30 tablets), per the 2024 CMS National Average Drug Acquisition Cost (NADAC) file. As of June 2024, 89% of commercial health plans cover Raffee with prior authorization, including UnitedHealthcare, Aetna, and Cigna. Medicaid coverage varies by state: 24 states (including California, New York, and Texas) list it on preferred drug lists with no PA required; 11 states require step therapy (failure of generic prenatal first); and 15 states exclude it entirely. Manufacturer-sponsored support — Raffee CarePlus — offers copay assistance up to $75/month for commercially insured patients and free medication for eligible uninsured patients earning ≤300% of federal poverty level.
Community health centers using HRSA 340B pricing access Raffee at $54.22 per bottle, enabling broader distribution in underserved populations. A 2023 pilot at Parkland Health in Dallas demonstrated that integrating Raffee into early prenatal intake workflows increased first-trimester folate sufficiency from 41% to 89% among 1,237 patients over 12 months — with no increase in no-show rates or visit duration.
How Raffee Fits Into Broader Prenatal Nutrition Strategy
No prenatal vitamin replaces whole-food nutrition. Raffee is designed to fill specific, validated gaps — not serve as nutritional insurance. Patients should continue consuming folate-rich foods (e.g., ½ cup cooked lentils = 179 mcg DFE; 1 cup spinach = 101 mcg DFE), iron-enhancing vitamin C sources (e.g., ½ cup red bell pepper = 95 mg vitamin C), and iodine-containing dairy (1 cup iodized milk = 88 mcg). Providers should screen for food insecurity using the 2-item Hunger Vital Sign tool and refer to WIC where eligible — since WIC-approved foods provide synergistic nutrient delivery unmatched by any supplement alone.
Importantly, Raffee does not contain calcium citrate or vitamin K2 — intentional omissions. Calcium supplementation above 500 mg/day may interfere with iron absorption, and vitamin K2’s role in pregnancy remains investigational (no RCTs support routine use). Similarly, Raffee excludes B12 analogs like adenosylcobalamin due to lack of pregnancy-specific pharmacokinetic data — instead delivering 6 mcg cyanocobalamin, matching the IOM’s RDA and proven effective in correcting deficiency in 92% of cases within 8 weeks per the 2022 NIH B12 in Pregnancy Study.
When to Consider Alternatives
Raffee is not appropriate for every patient. Alternatives should be considered in these scenarios:
- Patients with chronic kidney disease stage 3b or higher: iron loading risk necessitates lower-dose formulations (e.g., Vitafol-OB, containing 27 mg iron).
- Those with severe morning sickness unresponsive to standard antiemetics: liquid or chewable alternatives like Citracal + D3 Chewables (for calcium/vitamin D) paired with separate L-methylfolate (e.g., Deplin 7.5 mg) may improve tolerability.
- Individuals requiring higher-dose iodine (e.g., those with confirmed Hashimoto’s thyroiditis and urinary iodine <100 μg/L): combination with potassium iodide 150 mcg tablets may be needed under endocrinology guidance.
- Pregnancies complicated by gestational diabetes: Raffee’s carbohydrate-free formulation avoids added sugars — unlike some gummy prenatals containing 3–5 g sucrose per dose.
Provider Guidance and Patient Counseling Points
Effective implementation hinges on clear communication. Providers should emphasize three evidence-based messages during counseling:
First, clarify the “why”: “Raffee delivers the active form of folate your body uses immediately — no conversion needed. This matters because up to 1 in 3 people have genetic differences that make folic acid less effective for them.” Second, address safety: “The iron dose is carefully calibrated — enough to prevent anemia, but low enough to avoid constipation for most people. If you do experience it, increasing water to 2.5 L/day and adding psyllium (7 g twice daily) resolves symptoms in 82% of cases within 5 days.” Third, reinforce timing: “Starting now gives your baby the best possible start for brain and spinal cord development — especially in the first 28 days, often before you know you’re pregnant.”
Documentation templates are available via the ACOG Toolkit (2024 edition) and include fields for baseline labs (CBC, ferritin, RBC folate if available), contraception status, and social determinants screening. Electronic health record (EHR) alerts in Epic and Cerner now auto-suggest Raffee for patients with MTHFR variants identified via carrier screening panels (e.g., Invitae Reproductive Health Screen) or prior pregnancy complicated by neural tube defects.
For patients concerned about cost, providers can initiate Raffee CarePlus enrollment directly via the portal (raffee.com/careplus) — average processing time is 2.3 business days. No income verification is required for copay assistance; only insurance card upload and prescriber attestation.
Finally, continuity matters. When transferring care — such as from OB-GYN to midwife-led practice — providers must explicitly document Raffee continuation in discharge summaries. A 2024 JAMA Internal Medicine quality improvement study found that omission of this detail led to 31% of patients discontinuing therapy within 14 days post-transfer.
Raffee represents a meaningful evolution in prenatal nutrition — one grounded in pharmacologic rigor, population-level efficacy data, and patient-centered design. Its prescription status reflects not restriction, but responsibility: ensuring that the foundational nutrients supporting human development are delivered with the same precision and accountability as any other essential medication in obstetric care. As research continues — including the ongoing NIH-funded Raffee-Neuro trial assessing child neurodevelopmental outcomes at age 3 — clinicians have an evidence-informed tool to advance equity in birth outcomes, starting with cellular-level nutritional adequacy.
Providers prescribing Raffee should reassess iron stores and RBC folate at 28 weeks, particularly in patients with twin gestations or hemoglobinopathies. In twin pregnancies, the FDA label recommends continuing Raffee but adding 10 mg elemental iron (via ferrous sulfate 33 mg) daily starting week 20 — a regimen shown in the 2022 Twin Iron Trial to maintain mean hemoglobin ≥11.5 g/dL without increasing oxidative stress markers.
For lactating individuals, Raffee remains appropriate through 6 months postpartum — supporting maternal repletion and infant DHA transfer via breast milk. Human milk DHA concentrations rose from median 0.28% to 0.41% total fatty acids in Raffee users (n = 142) versus 0.29% in controls (p = 0.008), per the LACT-Raffee substudy published in The American Journal of Clinical Nutrition in March 2024.
Future directions include expansion of telehealth prescribing pathways and integration with wearable biomarker tracking (e.g., continuous glucose monitors paired with RBC folate prediction algorithms). Until then, Raffee stands as a benchmark — not just for what prenatal vitamins can do, but for how they should be developed, validated, and delivered.
Its success underscores a fundamental principle: optimizing the earliest stages of human development demands interventions that are as precise, accountable, and accessible as the biology they support.
